Manufacturing
Theragent to act as partner for CellVax’s Phase II cancer therapy
CellVax will examine and evaluate how FK-PC101 reduces the recurrence of prostate-specific antigens in patients.
CellVax will examine and evaluate how FK-PC101 reduces the recurrence of prostate-specific antigens in patients.